Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites
- PMID: 12870885
- DOI: 10.1021/tx030004s
Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites
Abstract
The antiestrogen, tamoxifen, has been extensively used in the treatment and prevention of breast cancer. Although tamoxifen showed benefits in the chemotherapy and chemoprevention of breast cancer, epidemiological studies in both tamoxifen-treated breast cancer patients and healthy women indicated that treatment caused an increased risk of developing endometrial cancer. These troubling side effects lead to concerns over long-term safety of the drug. Therefore, it is important to fully understand the relationship between the antiestrogenic and the genotoxic mechanisms of tamoxifen, other antiestrogens, and their metabolites. Previously, we have shown that o-quinone formation from tamoxifen and its analogues, droloxifene and 4-hydroxytoremifene, may not contribute to the cytotoxic effects of these antiestrogens; however, these o-quinones can form adducts with deoxynucleosides and this implies that the o-quinone pathway could contribute to the genotoxicity of the antiestrogens in vivo. To further investigate this potential genotoxic pathway, we were interested in the role of estrogen receptor (ER)(1) alpha and beta since work with catechol estrogens has shown that ERs seem to enhance DNA damage in breast cancer cell lines. As a result, we investigated the binding affinities of 4-hydroxy and 3,4-dihydroxy derivatives of tamoxifen and toremifene to ER alpha and beta. The antiestrogenic activities of the metabolites using the Ishikawa cells were also investigated as well as their activity in ERalpha and ERbeta breast cancer cells using the transient transfection reporter, estrogen response element-dependent luciferase assay. The data showed that the antiestrogenic activities of these compounds in the biological assays mimicked their activities in the ER binding assay. To determine if the compounds were toxic and if ERs played a role in this process, the cytotoxicity of these compounds in ERbeta41(2) (ERbeta), S30 (ERalpha), and MDA-MB-231 (ER(-)) cell lines was compared. The results showed that the cytotoxicity differences between the metabolites were modest. In addition, all of the metabolites showed similar toxicity patterns in both ER positive and negative cell lines, which means that the ER may not contribute to the cytotoxicity pathway. Finally, we compared the amount of DNA damage induced by these metabolites in these cell lines using the comet assay. The catechols 3,4-dihydroxytoremifene and 3,4-dihydroxytamoxifen induced a greater amount of cellular single strand DNA cleavage as compared with the phenols in all cell lines. The different amounts of DNA damage in ER positive and negative cell lines suggested that the ERs might play a role in this process. These data suggest that the formation of catechols represents a minor role in cytotoxic and antiestrogenic effects in cells as compared with their phenol analogues. However, catechols induced more DNA damage at nontoxic doses in breast cancer cells, which implies that o-quinones formed from catechols could contribute to genotoxicity in vivo, which is ER-dependent.
Similar articles
-
Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.Chem Res Toxicol. 2001 Dec;14(12):1643-53. doi: 10.1021/tx010137i. Chem Res Toxicol. 2001. PMID: 11743747
-
Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.Breast Cancer Res Treat. 2003 Oct;81(3):209-21. doi: 10.1023/A:1026114501364. Breast Cancer Res Treat. 2003. PMID: 14620916
-
Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.Mol Pharmacol. 1991 Mar;39(3):421-8. Mol Pharmacol. 1991. PMID: 2005879
-
Basic guide to the mechanisms of antiestrogen action.Pharmacol Rev. 1998 Jun;50(2):151-96. Pharmacol Rev. 1998. PMID: 9647865 Review.
-
[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].Bull Cancer. 1996 Oct;83(10):808-15. Bull Cancer. 1996. PMID: 8952630 Review. French.
Cited by 9 articles
-
Protein Engineering Strategies to Expand CRISPR-Cas9 Applications.Int J Genomics. 2018 Aug 2;2018:1652567. doi: 10.1155/2018/1652567. eCollection 2018. Int J Genomics. 2018. PMID: 30155473 Free PMC article. Review.
-
Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.North Clin Istanb. 2018 Jan 22;5(1):6-13. doi: 10.14744/nci.2017.55822. eCollection 2018. North Clin Istanb. 2018. PMID: 29607425 Free PMC article.
-
Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects.Chem Res Toxicol. 2017 Jan 17;30(1):13-37. doi: 10.1021/acs.chemrestox.6b00256. Epub 2016 Sep 29. Chem Res Toxicol. 2017. PMID: 27617882 Free PMC article.
-
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.J Ovarian Res. 2016 Feb 15;9:5. doi: 10.1186/s13048-016-0213-3. J Ovarian Res. 2016. PMID: 26879975 Free PMC article.
-
Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?Curr Org Chem. 2014 Jan 1;18(1):61-69. doi: 10.2174/138527281801140121123046. Curr Org Chem. 2014. PMID: 25346613 Free PMC article.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Miscellaneous